PRTA logo

PRTA
Prothena Corporation plc

1,982
Mkt Cap
$510.97M
Volume
700,064.00
52W High
$11.80
52W Low
$4.32
PE Ratio
-3.47
PRTA Fundamentals
Price
$9.76
Prev Close
$9.86
Open
$9.73
50D MA
$10.05
Beta
1.08
Avg. Volume
418,773.23
EPS (Annual)
-$4.53
P/B
1.66
Rev/Employee
$144,537.31
$214.91
Loading...
Loading...
News
all
press releases
Prothena Posts Q1 Earnings as Revenues Surge on Milestone Payment
PRTA posted a Q1 profit as a $50M Novo Nordisk milestone payment boosted revenue and improved its 2026 cash outlook.
Zacks·8d ago
News Placeholder
More News
News Placeholder
Prothena Reports First Quarter 2026 Financial Results and Business Highlights
Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today reported financial results for the first quarter of 2026 and provided business highlights. In the quarter we...
Business Wire·9d ago
News Placeholder
Prothena to Report First Quarter 2026 Financial Results on May 7
Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced...
Business Wire·16d ago
News Placeholder
Prothena (NASDAQ:PRTA) Shares Up 5.9% - Time to Buy?
Prothena (NASDAQ:PRTA) Trading Up 5.9% - Here's What Happened...
MarketBeat·18d ago
News Placeholder
Prothena Announces Novo Nordisk Obtains Fast Track Designation from the U.S. FDA for Coramitug (PRX004) in ATTR Amyloidosis with Cardiomyopathy
Prothena Corporation plc (NASDAQ:PRTA) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to coramitug, a potential best-in-class amyloid depleter...
Business Wire·19d ago
News Placeholder
Prothena Corporation plc (NASDAQ:PRTA) Given Consensus Rating of "Hold" by Analysts
Shares of Prothena Corporation plc (NASDAQ:PRTA - Get Free Report) have earned a consensus rating of "Hold" from the eleven analysts that are covering the company, Marketbeat.com reports. Two...
MarketBeat·26d ago
News Placeholder
Prothena (NASDAQ:PRTA) Share Price Passes Above 200-Day Moving Average - Time to Sell?
Prothena (NASDAQ:PRTA) Share Price Passes Above 200 Day Moving Average - Here's Why...
MarketBeat·29d ago
News Placeholder
Prothena Announces Leadership Team Updates
Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced...
Business Wire·1mo ago
News Placeholder
AZN Posts Data From Hypophosphatasia Program on Efzimfotase Alfa
AstraZeneca reports phase III data showing efzimfotase alfa improves bone health in children with HPP, with mixed adult results and an overall favorable safety profile.
Zacks·2mo ago
News Placeholder
Sanofi Gets EU Nod for Rezurock in Chronic Graft-Vs-Host Disease
SNY secures EU conditional approval for Rezurock to treat chronic GVHD in adults and children aged 12 years and older.
Zacks·2mo ago
<
1
2
...
>

Latest PRTA News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.